Mark W. Hahn - 01 Nov 2022 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Issuer symbol
VRNA
Transactions as of
01 Nov 2022
Transactions value $
-$749,781
Form type
4
Filing time
03 Nov 2022, 16:05:20 UTC
Previous filing
28 Sep 2022
Next filing
21 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Tax liability -$728K -455K -2.54% $1.60* 17.5M 01 Nov 2022 Direct F1, F2, F3
transaction VRNA Ordinary Shares Sale -$22K -13.2K -0.08% $1.67* 17.4M 01 Nov 2022 Direct F1, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
F3 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2022 divided by eight (8).
F4 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units.
F5 The price reported represents the sale price of the ADSs divided by eight (8).
F6 Consists of (i) 9,413,016 Ordinary Shares underlying RSUs (which are represented by 1,176,627 ADSs); and (ii) 8,032,464 Ordinary Shares underlying 1,004,058 ADSs.